Skip to main content
SpringerLink
Log in

Reducing variation in the pharmacologic treatment of schizophrenia: Defining acceptable standards of treatment

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Clinicians are exhorted to improve the quality of care for patients with schizophrenia by applying evidence-based medication treatment guidelines. Unfortunately, although there are many guidelines, they are all more or less out of date, and their recommendations often are inconsistent, leaving clinicians uncertain about the definition of acceptable standards of care. This paper reviews existing guideline recommendations and recently published research related to two parameters of care: 1) first-line treatment of multiepisode psychosis and 2) the care of treatment-resistant patients. Its purpose is to help clinicians understand the implications of the latest research for the content of schizophrenia guidelines and for the clinical practice they are supposed to inform.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and recommended reading

  1. Tandon R, Dewan N, Constantine R: Best practice pharmacologic treatment of schizophrenia: applying principles of evidence-based medicine. Curr Psychosis Ther Rep 2005, 3:1–7.

    Google Scholar 

  2. Frakenburg F: Schizophrenia. WebMD. www.emedicine.com/med/topic2072.htm. Accessed January 2007.

  3. Becker MA, Young MS, Ochshorn E, Diamond RJ: The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Adm Policy Ment Health 2007 [Epub ahead of print].

  4. Knapp M: Costs of schizophrenia. Psychiatry 2005, 4:33–35.

    Article  Google Scholar 

  5. Knapp M, King D, Pugne K, et al.: Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004, 184:509–516.

    Article  PubMed  Google Scholar 

  6. Perkins D, Johnson JL, Hamer RM, et al.: Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006, 83:53–63.

    Article  PubMed  Google Scholar 

  7. Weiden P, Kane J: Pharmacologic and psychosocial interventions in the treatment of schizophrenia. Medscape website. www.medscape.com/viewarticle/537387. Accessed July 2006.

  8. Dembling BP, Chen DT, Vachon L: Life expectancy and causes of death in a population treated for serious mental illness. Psychiatr Serv 1999, 50:1036–1042.

    PubMed  CAS  Google Scholar 

  9. Colton CW, Manderscheid RW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3:1–14.

    Google Scholar 

  10. Lehman AF, Steinwachs DM: Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998, 24:1–10.

    PubMed  CAS  Google Scholar 

  11. Mellman TA, Miller AL, Weissman EM, et al.: Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms. Psychiatr Serv 2001, 52:619–625.

    Article  PubMed  CAS  Google Scholar 

  12. Constantine RJ, Surles R, Richard S, et al.: Optimizing pharmacotherapy of schizophrenia: tools for the psychiatrist. Curr Psychosis Ther Rep 2006, 4:5–11.

    Google Scholar 

  13. Milner KK, Valenstein M: A comparison of guidelines for the treatment of schizophrenia. Psychiatr Serv 2002, 53:888–890.

    Article  PubMed  Google Scholar 

  14. Nasrallah HA: 3 types of “EBM.” Curr Psychiatry 2007, 6:15–16.

    Google Scholar 

  15. Gaebel W, Weinmann S, Sartorius N, et al.: Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005, 187:248–255.

    Article  PubMed  Google Scholar 

  16. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. National Institute for Clinical Excellence website. www.nice.org.uk. Updated December 2002. Accessed July 2006.

  17. American Psychiatric Association: Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 2004, 161:1–56.

    Article  Google Scholar 

  18. Canadian Psychiatric Association: Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005, 50:7S–57S.

    Google Scholar 

  19. Miller AL, Hall CS, Buchanan RW, et al.: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004, 65:500–505.

    Article  PubMed  Google Scholar 

  20. Rush AJ, Crismon ML, Kashner TM, et al.: Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry 2003, 64:357–369.

    Article  PubMed  Google Scholar 

  21. Lehman AF, Kreyenbuhl J, Buchanan RW, et al.: The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004, 30:193–217.

    PubMed  Google Scholar 

  22. Kane JM: PORT recommendations. Schizophr Bull 2004, 30:605–607.

    PubMed  Google Scholar 

  23. Miller AL: PORT treatment recommendations. Schizophr Bull 2004, 30:601–604.

    PubMed  Google Scholar 

  24. Stroup TS, McEvoy JP, Swartz MS, et al.: The National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003, 29:15–31.

    PubMed  Google Scholar 

  25. Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209–1223.

    Article  PubMed  CAS  Google Scholar 

  26. Kane JM: Commentary on the CATIE trial. J Clin Psychiatry 2006, 67:831–832.

    Article  PubMed  Google Scholar 

  27. Glick ID: Understanding the results of CATIE in the context of the field. CNS Spectr 2006, 11(Suppl 7):40–47.

    PubMed  Google Scholar 

  28. Tandon R: Comparative effectiveness of antipsychotics in the treatment of schizophrenia: what CATIE (phase 1) tells us — Part 1. Int Drug Ther Newsl 2006, 41:51–58.

    Google Scholar 

  29. Lewis SW, Davies L, Jones PB, et al.: Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus dozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006, 10:ix–xi, 1–165.

    Google Scholar 

  30. Lewis SW, Barnes TR, Davies L, et al.: Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006, 32:715–723.

    Article  PubMed  Google Scholar 

  31. Jones PB, Barnes TR, Davies L, et al.: Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006, 63:1079–1087.

    Article  PubMed  CAS  Google Scholar 

  32. Constantine R, Tandon R: Antipsychotics equivalent? CUtLASS renews the debate. Curr Psychiatry 2007, 6:57–68.

    Google Scholar 

  33. Tandon R, Constantine R: Avoiding EPS is key to realizing “atypical” benefits. Curr Psychiatry 2006, 5:35–45.

    Google Scholar 

  34. Delisi LE, Nasrallah HA: The CATIE schizophrenia effectiveness trial. Schizophr Res 2005, 80:v–vi.

    Article  PubMed  CAS  Google Scholar 

  35. Meltzer H, Bobo W: Interpreting the efficacy findings of the CATIE study: what clinicians should know. CNS Spectr 2006, 11:14–24.

    PubMed  Google Scholar 

  36. Tandon R: Comparative effectiveness of antipsychotics in the treatment of schizophrenia: what CATIE (phases 1 and 2) tell us-Part 2. Int Drug Ther Newsl 2006, 41:67–74.

    Google Scholar 

  37. Tandon R, Targum SD, Nasrallah HA, et al.: Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Pract 2006, 12:348–363.

    Article  PubMed  Google Scholar 

  38. Kane JM, Leucht S, Carpenter D, et al.: The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003, 64(Suppl 12):5–19.

    PubMed  Google Scholar 

  39. Essock S, Covell N, Davis S, et al.: Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006, 163:1–7.

    Article  Google Scholar 

  40. McEvoy JP, Lieberman JA, Stroup TS, et al.: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, 163:600–610.

    Article  PubMed  Google Scholar 

  41. Wahlbeck K, Cheine M, Essali MA: Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000, 2:CD000059.

  42. Wahlbeck K, Cheine M, Essali A, Adams C: Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999, 156:990–999.

    PubMed  CAS  Google Scholar 

  43. Chakos M, Lieberman J, Hoffman E, et al.: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001, 158:518–526.

    Article  PubMed  CAS  Google Scholar 

  44. Rosenheck R, Leslie DL, Sindelar J, et al.: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006, 163:2080–2089.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Florida Mental Health Institute, University of South Florida, 13301 Bruce B. Downs Boulevard, MHC 2724, Tampa, FL, 33612, USA

    Robert J. Constantine PhD, MPH

Authors
  1. Robert J. Constantine PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Constantine PhD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Constantine, R.J. Reducing variation in the pharmacologic treatment of schizophrenia: Defining acceptable standards of treatment. Curr Psychiatry Rep 9, 319–324 (2007). https://doi.org/10.1007/s11920-007-0039-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-007-0039-1

Keywords

Search

Navigation